Positive allosteric modulation of metabotropic glutamate receptor 5; a novel approach for the treatment of schizophrenia and cognitive disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1013709

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The metabotropic glutamate receptor subtype 5 (mGluR5) has emerged as an exciting new target for the treatment of schizophrenia and cognitive disorders. We will investigate novel drug-binding sites on these receptors with the aim to discover new therapeutics. These studies also aim to definitively characterize mGluR5 activity following treatment with novel compounds to improve our understanding of the normal function of these important receptors.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2015

Funding Scheme: Early Career Fellowships

Funding Amount: $348,428.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Basic Pharmacology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

G protein-coupled receptors | cognitive disorders | drug development | glutamate receptors | molecular pharmacology | psychiatric disorders | schizophrenia | schizophrenia and related disorders

Related Links